| Denise D Mchugh, MD | |
|
10 Prospect St, Nashua, NH 03060-3922 | |
| (603) 577-3131 | |
| (603) 577-3132 |
| Full Name | Denise D Mchugh |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 32 Years |
| Location | 10 Prospect St, Nashua, New Hampshire |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1982763611 | NPI | - | NPPES |
| 30202080 | Medicaid | NH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 9817 (New Hampshire) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Southern Nh Medical Center | Nashua, NH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Foundation Medical Partners Inc | 9436140456 | 280 |
News Archive
Ben-Gurion University of the Negev (BGU) researchers have developed a unique technology that stabilizes an otherwise unstable form of calcium carbonate. This mineral form provides significantly higher biological absorption and retention rates than other sources presently used as dietary calcium supplements.
UBC researchers have invented a silicone chip that could make genetic analysis far more sensitive, rapid, and cost-effective by allowing individual cells to fall into place like balls in a pinball machine.
TenX Biopharma, Inc. announced today that data from a Phase II trial of zanolimumab (HuMax-CD4®) in peripheral T-cell Lymphoma were published in the British Journal of Haematology (Sep 2010: 150(5):565-73). The Hx-CD4-109 trial was designed to evaluate the safety and efficacy of zanolimumab in patients who have relapsed or refractory non-cutaneous peripheral T-cell lymphoma.
Isotechnika Pharma Inc. today announced that the New Drug Application (NDA) for the Company's next generation calcineurin inhibitor, voclosporin, has been accepted for priority review as filed by the U.S. Food and Drug Administration (FDA). The application was submitted by Isotechnika's partner, Lux Biosciences, Inc.
› Verified 9 days ago
| Entity Name | Dartmouth-hitchcock Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386697803 PECOS PAC ID: 4183537509 Enrollment ID: O20031111000313 |
News Archive
Ben-Gurion University of the Negev (BGU) researchers have developed a unique technology that stabilizes an otherwise unstable form of calcium carbonate. This mineral form provides significantly higher biological absorption and retention rates than other sources presently used as dietary calcium supplements.
UBC researchers have invented a silicone chip that could make genetic analysis far more sensitive, rapid, and cost-effective by allowing individual cells to fall into place like balls in a pinball machine.
TenX Biopharma, Inc. announced today that data from a Phase II trial of zanolimumab (HuMax-CD4®) in peripheral T-cell Lymphoma were published in the British Journal of Haematology (Sep 2010: 150(5):565-73). The Hx-CD4-109 trial was designed to evaluate the safety and efficacy of zanolimumab in patients who have relapsed or refractory non-cutaneous peripheral T-cell lymphoma.
Isotechnika Pharma Inc. today announced that the New Drug Application (NDA) for the Company's next generation calcineurin inhibitor, voclosporin, has been accepted for priority review as filed by the U.S. Food and Drug Administration (FDA). The application was submitted by Isotechnika's partner, Lux Biosciences, Inc.
› Verified 9 days ago
| Entity Name | Foundation Medical Partners Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033162037 PECOS PAC ID: 9436140456 Enrollment ID: O20040519001048 |
News Archive
Ben-Gurion University of the Negev (BGU) researchers have developed a unique technology that stabilizes an otherwise unstable form of calcium carbonate. This mineral form provides significantly higher biological absorption and retention rates than other sources presently used as dietary calcium supplements.
UBC researchers have invented a silicone chip that could make genetic analysis far more sensitive, rapid, and cost-effective by allowing individual cells to fall into place like balls in a pinball machine.
TenX Biopharma, Inc. announced today that data from a Phase II trial of zanolimumab (HuMax-CD4®) in peripheral T-cell Lymphoma were published in the British Journal of Haematology (Sep 2010: 150(5):565-73). The Hx-CD4-109 trial was designed to evaluate the safety and efficacy of zanolimumab in patients who have relapsed or refractory non-cutaneous peripheral T-cell lymphoma.
Isotechnika Pharma Inc. today announced that the New Drug Application (NDA) for the Company's next generation calcineurin inhibitor, voclosporin, has been accepted for priority review as filed by the U.S. Food and Drug Administration (FDA). The application was submitted by Isotechnika's partner, Lux Biosciences, Inc.
› Verified 9 days ago
| Entity Name | Dartmouth-hitchcock Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548210198 PECOS PAC ID: 4183537509 Enrollment ID: O20040809000442 |
News Archive
Ben-Gurion University of the Negev (BGU) researchers have developed a unique technology that stabilizes an otherwise unstable form of calcium carbonate. This mineral form provides significantly higher biological absorption and retention rates than other sources presently used as dietary calcium supplements.
UBC researchers have invented a silicone chip that could make genetic analysis far more sensitive, rapid, and cost-effective by allowing individual cells to fall into place like balls in a pinball machine.
TenX Biopharma, Inc. announced today that data from a Phase II trial of zanolimumab (HuMax-CD4®) in peripheral T-cell Lymphoma were published in the British Journal of Haematology (Sep 2010: 150(5):565-73). The Hx-CD4-109 trial was designed to evaluate the safety and efficacy of zanolimumab in patients who have relapsed or refractory non-cutaneous peripheral T-cell lymphoma.
Isotechnika Pharma Inc. today announced that the New Drug Application (NDA) for the Company's next generation calcineurin inhibitor, voclosporin, has been accepted for priority review as filed by the U.S. Food and Drug Administration (FDA). The application was submitted by Isotechnika's partner, Lux Biosciences, Inc.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Denise D Mchugh, MD 10 Prospect St, Nashua, NH 03060-3922 Ph: (603) 577-3131 | Denise D Mchugh, MD 10 Prospect St, Nashua, NH 03060-3922 Ph: (603) 577-3131 |
News Archive
Ben-Gurion University of the Negev (BGU) researchers have developed a unique technology that stabilizes an otherwise unstable form of calcium carbonate. This mineral form provides significantly higher biological absorption and retention rates than other sources presently used as dietary calcium supplements.
UBC researchers have invented a silicone chip that could make genetic analysis far more sensitive, rapid, and cost-effective by allowing individual cells to fall into place like balls in a pinball machine.
TenX Biopharma, Inc. announced today that data from a Phase II trial of zanolimumab (HuMax-CD4®) in peripheral T-cell Lymphoma were published in the British Journal of Haematology (Sep 2010: 150(5):565-73). The Hx-CD4-109 trial was designed to evaluate the safety and efficacy of zanolimumab in patients who have relapsed or refractory non-cutaneous peripheral T-cell lymphoma.
Isotechnika Pharma Inc. today announced that the New Drug Application (NDA) for the Company's next generation calcineurin inhibitor, voclosporin, has been accepted for priority review as filed by the U.S. Food and Drug Administration (FDA). The application was submitted by Isotechnika's partner, Lux Biosciences, Inc.
› Verified 9 days ago
Kellie Anne Motschmann, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 8 Prospect St, Nashua, NH 03060 Phone: 603-577-2024 | |
Derek T Jurus, D.O. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 10 Prospect St, Nashua, NH 03060 Phone: 603-577-3131 | |
Dr. Kelly M Macmillan, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 168 Kinsley St Ste 20, Nashua, NH 03060 Phone: 603-883-3365 Fax: 603-883-5758 | |
Dr. David Saul Deifik, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 22 Prospect St, Nashua, NH 03060 Phone: 603-883-1626 Fax: 603-816-1039 | |
Ms. Lydia Garcia, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 280 Main St, Suite 131, Nashua, NH 03060 Phone: 603-577-5353 Fax: 603-577-3105 | |
Mrs. Monelle G Bisson, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 8 Prospect St, Nashua, NH 03060 Phone: 603-577-3053 Fax: 603-882-0360 | |
Alison C. Madden, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 168 Kinsley St Ste 20, Nashua, NH 03060 Phone: 603-883-3365 Fax: 603-883-5758 |